Pirttilä T, Kim K S, Mehta P D, Frey H, Wisniewski H M
Institute for Basic Research in Developmental Disabilities, Staten Island, NY 10314.
J Neurol Sci. 1994 Dec 1;127(1):90-5. doi: 10.1016/0022-510x(94)90140-6.
Cerebrospinal fluid (CSF) soluble amyloid beta-protein (sA beta) concentrations from 69 patients with Alzheimer's disease (AD), 23 patients with vascular dementia (VD), and 76 non-demented controls were measured by a sandwich enzyme linked immunosorbent assay using two monoclonal antibodies (4G8 and 6E10) specific for A beta. sA beta concentrations were lower in CSF from patients with AD or VD compared to those in controls. CSF sA beta concentrations did not correlate with the Mini-Mental State Examination scores in patients with AD. VD patients with moderate to severe dementia had lower CSF sA beta concentrations than those with mild dementia. Because a considerable overlap of CSF sA beta levels existed between AD and control groups, the assay is not useful as a diagnostic test for AD.
采用夹心酶联免疫吸附测定法，使用两种针对β淀粉样蛋白（Aβ）的单克隆抗体（4G8和6E10），对69例阿尔茨海默病（AD）患者、23例血管性痴呆（VD）患者和76例非痴呆对照者的脑脊液（CSF）可溶性β淀粉样蛋白（sAβ）浓度进行了测定。与对照组相比，AD或VD患者脑脊液中的sAβ浓度较低。AD患者脑脊液中的sAβ浓度与简易精神状态检查表评分无关。中度至重度痴呆的VD患者脑脊液中的sAβ浓度低于轻度痴呆患者。由于AD组和对照组之间脑脊液sAβ水平存在相当大的重叠，该检测方法作为AD的诊断测试并无用处。
